Trial Profile
Efficacy and safety of switching from originator infliximab to CT-P13 in patients with in inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2018 New trial record